Biogen's Aduhelm Defense Highlights Therapeutic Area Discrepancies

 
• By Jessica Merrill

The company's comments to CMS on the proposed NCD for amyloid-targeting therapies for Alzheimer's disease says the differences between Alzheimer's and other areas could represent a legal issue.

change of direction
Biogen hopes CMS will change its decision on Aduhelm coverage • Source: Alamy

More from Medicare

More from Government Payers